

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335371190 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 6, 2005

Signature: Georgina Matos (Georgina Matos)

PATENT
Docket No. 252312008000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Matthew D. LINNIK et al.

Serial No.: 10/814,555

Filing Date: March 30, 2004

For: METHODS OF TREATING AND
MONITORING SYSTEMIC LUPUS
ERYTHEMATOSUS IN INDIVIDUALS

Examiner: Not Yet Assigned

Group Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO 1449. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO 1449 were cited in an International Search Report mailed on November 4, 2004 directed to a counterpart international or foreign application and were not previously submitted. A certification under 37 C.F.R. § 1.97(e)(1) follows:

Application Serial No. 10/814,555

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO 1449, indicating that the information has been considered and made of record herein.


Application Serial No. 10/814,555

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **252312008000**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 6, 2005

Respectfully submitted,

By 
Jie Zhou
Registration No.: 52,395

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304
(650)813-5922

Form PTO-1449

Docket Number 252312008000

Application Number 10/814,555

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Matthew D. LINNIK et al.

Filing Date March 30, 2004

Group Art Unit 1645

Mailing Date January 6, 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Document Date (MM/DD/YYYY)	Document No.	Name	Filing Date If Appropriate
	1.	06/09/1998	60/088,656	Marquis et al.	
	2.	06/08/1999	60/138,260	Jones et al.	
	3.	06/08/1999	09/328,199	Marquis et al.	
	4.	12/08/1999	09/457,875	Engle et al.	
	5.	06/08/2000	09/590,592	Jones et al.	
	6.	11/28/2000	09/724,822	Linnik et al.	
	7.	07/30/2003	10/631,388	Coutts et al.	
	8.	03/30/2004	10/814,555	Linnik et al.	
	9.	08/02/2001	2001/0010808	Yagi et al.	
	10.	08/02/2001	2001/0010818	Engle et al.	
	11.	06/27/2002	2002/0082400	Coutts et al.	
	12.	08/01/2002	2002/0103343	Taylor et al.	
	13.	08/08/2002	2002/0107389	Coutts et al.	
	14.	08/15/2002	2002/0110535	Jones et al.	
	15.	10/01/2002	2002/0021001	Jones et al.	
	16.	10/24/2002	2002/0155107	Engle et al.	
	17.	12/12/2002	2002/0187156	Dintzis et al.	
	18.	01/23/2003	2003/0018190	Jones et al.	
	19.	06/05/2003	2003/0103990	Coutts et al.	
	20.	06/19/2003	2003/0114405	Linnik et al.	
	21.	08/28/2003	2003/0162953	Coutts et al.	
	22.	05/02/1978	4,086,924	Latham, Jr.	
	23.	09/23/1980	4,223,672	Terman et al.	
	24.	06/30/1992	5,126,131	Dintzis et al.	
	25.	11/10/1992	5,162,515	Conrad et al.	
	26.	12/07/1993	5,268,454	Barstad et al.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 4, 2005	

	27.	01/04/1994	5,276,013	Conrad et al.	
	28.	12/06/1994	5,370,871	Dintzis et al.	
	29.	02/21/1995	5,391,785	Jones et al.	
	30.	11/28/1995	5,470,570	Taylor et al.	
	31.	01/30/1996	5,487,890	Taylor et al.	
	32.	04/30/1996	5,512,294	Li et al.	
	33.	09/03/1996	5,552,391	Coutts et al.	
	34.	02/25/1997	5,606,047	Coutts et al.	
	35.	05/27/1997	5,633,395	Coutts et al.	
	36.	03/10/1998	5,726,329	Jones et al.	
	37.	03/31/1998	5,733,254	Jones et al.	
	38.	07/28/1998	5,786,512	Jones et al.	
	39.	10/06/1998	5,817,752	Yu	
	40.	01/05/1999	5,856,464	Livingston	
	41.	02/23/1999	5,874,409	Victoria et al.	
	42.	02/23/1999	5,874,552	Jones et al.	
	43.	03/09/1999	5,879,679	Taylor et al.	
	44.	02/08/2000	6,022,544	Dintzis et al.	
	45.	05/09/2000	6,060,056	Coutts et al.	
	46.	03/27/2001	6,207,160	Victoria et al.	
	47.	01/22/2002	6,340,460	Dintzis	
	48.	03/26/2002	6,362,254	Harris et al.	
	49.	04/23/2002	6,375,951	Dintzis	
	50.	06/04/2002	6,399,578	Jones et al.	
	51.	06/25/2002	6,410,775	Victoria et al.	
	52.	10/01/2002	6,458,953	Jones	
	53.	06/03/2003	6,572,856	Taylor et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 6, 2005	

Examiner Initials	Ref. No.	Publication Date (MM/DD/YYYY)	Document No.	Country	Translation	
					YES	NO
	54.	12/20/1989	EP 0 346 810	Europe		
	55.	07/24/1991	EP 0 438 259	Europe		
	56.	03/15/1995	EP 0 642 798	Europe		
	57.	07/25/1991	WO 91/10426	WIPO		
	58.	08/20/1992	WO 92/13558	WIPO		
	59.	02/04/1993	WO 93/02093	WIPO		
	60.	03/16/1995	WO 95/07073	WIPO		
	61.	08/31/1995	WO 95/22977	WIPO		
	62.	12/19/1996	WO 96/40197	WIPO		
	63.	12/19/1996	WO 96/40708	WIPO		
	64.	12/11/1997	WO 97/46248	WIPO		
	65.	12/11/1997	WO 97/46251	WIPO		
	66.	08/12/1999	WO 99/40434	WIPO		
	67.	12/16/1999	WO 99/64595	WIPO		
	68.	06/15/2000	WO 00/33887	WIPO		
	69.	06/15/2000	WO 00/34231	WIPO		
	70.	06/15/2000	WO 00/34296	WIPO		
	71.	12/14/2000	WO 00/75105	WIPO		
	72.	06/14/2001	WO 01/41813	WIPO		
	73.	06/28/2001	WO 01/45669	WIPO		
	74.	11/01/2001	WO 01/80883	WIPO		
	75.	12/13/2001	WO 01/93914	WIPO		
	76.	06/13/2002	WO 02/46208	WIPO		
	77.	09/26/2002	WO 02/075275	WIPO		
	78.	11/21/2002	WO 02/092011	WIPO		
	79.	11/20/2003	WO 03/095626	WIPO		
	80.	03/25/2004	WO 04/024889	WIPO		
	81.	07/22/2004	WO 04/060320	WIPO		
	82.	10/21/2004	WO 04/089422	WIPO		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 4, 2005	

OTHER DOCUMENTS

(including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	83.	Abu-Shakra, M. et al. (February 1999). "Quality of Life in Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 26(2):306-309.
	84.	Alarcon-Segovia, M.D. et al (October 2000). "SLE Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High-Affinity Antibodies to LJP 394:90-05 Trial Results," abstract presented at <i>The 64th Annual Meeting of the American College of Rheumatology</i> , Oct. 29-Nov. 2, 2000, Philadelphia, PA, as posted on < http://www.ljpc.com/abstracts/abstract2000_sle_trial.html > visited on June 26, 2004 (2 pages).
	85.	Alarcon-Segovia, D. et al (March 2001). "SLE Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High-Affinity Antibodies to LJP 394:90-05 Trial Results," abstract presented at <i>The 6th International Lupus Conference</i> , Mar. 24-28, 2001, Barcelona, Spain, as posted on < http://www.ljpc.com/abstracts/abstract_2001_02.html > visited on April 9, 2004 (2 pages).
	86.	Alarcon-Segovia, D. et al. (September 2000) "SLE Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High Affinity Antibodies to LJP 394: 90-05 Trial Results," <i>Arthritis & Rheumatism</i> 43(9 supplement):S272:Abs. no. 1231.
	87.	Alarcon-Segovia, D. et al. (March 2001). "SLE Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High-Affinity Antibodies to LJP 394:90-05 Trial Results," <i>Lupus</i> 10 (Supp 1):pS94:Abs. no. 39.
	88.	Alarcon-Segovia, D. et al. (June 2002). "SLE Trial Shows Fewer Renal Flares in LJP 394-Treated Patients with High-Affinity Antibodies to LJP 394," <i>Clinical Immunology</i> 103(3):S87:Abs. no. 266.
	89.	Alarcon-Segovia, D. et al. (February 2003). "LJP 394 for the Prevention of Renal Flare in Patients with Systemic Lupus Erythematosus- Results from a Randomized, Double-Blind, Placebo-Controlled Study," <i>Arthritis & Rheumatism</i> 48(2):442-454.
	90.	Angst, F. et al. (August 2001). "Smallest Detectable and Minimal Clinically Important Differences of Rehabilitation Intervention with their Implications for Required Sample Sizes Using WOMAC and SF-36 Quality of Life Measurement Instruments in Patients with Osteoarthritis of the Lower Extremities," <i>Arth. Care Res.</i> 45:384-391.
	91.	Boers, M. et al. (January 1999). "OMERACT IV: Fourth International Consensus Conference on Outcome Measures in Rheumatology," <i>J. Rheumatol.</i> 26(1):199-200.
	92.	Bootsma, H. et al. (June 1995). "Prevention of Relapses in Systemic Lupus Erythematosus," <i>Lancet</i> 345:1595-1599.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January <u>6</u> , 2005	

93.	Borel, H. et al. (February 1990). "A Novel Technique to Link either Proteins or Peptides to Gammaglobulin to Construct Tolerogens," <i>Immunol. Methods</i> 126:159-168.
94.	Borel, Y. et al. (May 1995). "Food Allergens Transformed into Tolerogens," <i>Int. Arch. Allergy Immunol.</i> 107:264-267.
95.	Borel, Y. et al. (February 1996). "Parenteral and Oral Administration of Tolerogens: Protein-IgG Conjugates," <i>Ann. N.Y. Acad. Sci.</i> 778:80-87.
96.	Burckhardt, C.S. et al. (June 1993). "Quality of Life of Women with Systemic Lupus Erythematosus: A Comparison with Women with Rheumatoid Arthritis," <i>J Rheumatol</i> 20:977-981.
97.	Cardiel, M.H. et al. (September 2003). "Clinical Efficacy Results from a RCT of LJP 394 in SLE Patients with History of Renal Disease," <i>Arthritis & Rheumatism</i> 48(9):S582-583: Abs. no. 1503.
98.	Cardiel, M. (June 2003). "Randomized, Placebo Controlled, Double-Blind Phase III Clinical Trial for the Evaluation of LJP 394 (Abetimus Sodium) in the Treatment of Patients with SLE Who Are at Risk for Renal Flare," abstract <i>presented at the Annual European Congress of Rheumatology "EULAR 2003"</i> , June 18-21, 2003, Lisbon, Portugal, as posted on < http://www.ljpc.com/abstracts/abstract_2003_02.html > visited on December 8, 2003 (2 pages).
99.	Cardiel, M.H. et al. (September 2003). "Clinical Efficacy Results from a RCT of LJP 394 in SLE Patients with History of Renal Disease," abstract <i>presented at the 67th Annual Meeting of the American College of Rheumatology</i> , October 23-28, 2003, Orlando, FL, as posted on < http://www.ljpc.com/abstracts/abstract_2003_07.html > visited on December 8, 2003 (2 pages).
100.	Cash, J. et al. (May 1996). "A Dose-Ranging Study of LJP 394, A Novel Therapeutic Agent for the Treatment of Systemic Lupus Erythematosus," abstract <i>presented at The 26th Scandinavian Congress of Rheumatology Conference</i> , May 31-June 3, 1996, Reykjavik, Iceland, as posted on < http://www.ljpc.com/abstracts/abstract_1996_dose_ranging.html > visited on April 9, 2004 (2 pages).
101.	Coutts, S.M. et al. (April 1996). "Pharmacological Intervention in Antibody Mediated Disease," <i>Lupus</i> 5: 158-159.
102.	Coutts, S.M. et al. (May 1996). "Specific Anti-dsDNA B Cell Tolerance <i>In Vivo</i> ," abstract <i>presented at B Lymphocytes and Autoimmunity Conference</i> , May. 21-25, 1996, Prague, The Czech Republic, as posted on < http://www.ljpc.com/abstracts/abstract_1996_specific.html > visited on April 9, 2004 (2 pages).
103.	Craig, M.L. et al. (October 2000). "Clearance of Anti-Double-Stranded DNA Antibodies," <i>Arthritis & Rheumatism</i> 43(10):2265-2275.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 6, 2005	

104.	Craig, M.L. et al. (March 2002). "Tracking Immune Complexes from Erythrocytes to Macrophages: Visualization of the Transfer Reaction," <i>FASEB J.</i> 16(4):A683. Abs. No. 510.12.
105.	Craig, M.L. et al. (October 2002). "Visualization of the Transfer Reaction: Tracking Immune Complexes from Erythrocyte Complement Receptor 1 to Macrophages," <i>Clinical Immunol.</i> 105(1):36-47.
106.	DaCosta, D. et al. (February 2000). "Determinants of Health Status in Fibromyalgia: A Comparative Study with Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 27(2):365-372.
107.	DeGiorgio, L.A. et al. (November 2001). "A Subset of Lupus Anti-DNA Antibodies Cross-React with the NR2 Glutamate Receptor in Systemic Lupus Erythematosus," <i>Nature Medicine</i> 7(11):1189-1194.
108.	Dintzis, R.Z. et al. (November 1983). "Studies on the Immunogenicity and Tolerogenicity of T-Independent Antigens," <i>J. Immunol.</i> 131(5):2196-2203
109.	Dintzis, R.Z. et al. (August 1989). "The Immunogenicity of Soluble Haptenated Polymers is Determined by Molecular Mass and Hapten Valence," <i>J. Immunol.</i> 143(4):1239-1244.
110.	Dobkin, P.L. et al. (February 1998). "Psychosocial Contributors to Mental and Physical Health in Patients with Systemic Lupus Erythematosus," <i>Arth. Care Res.</i> 11(1):23-31.
111.	Dubois, E.L. et al. (October 1964). "Clinical Manifestations of Systemic Lupus Erythematosus," <i>JAMA</i> 190:104-111.
112.	Dumas, V. et al. (February 1995). "Induction of Tolerance by Administration of Hapten-Immunoglobulin Conjugates is Associated with Decreased IL-2 and IL-4 Production," <i>Arch. Dermatol. Res.</i> 287:123-128.
113.	Ehrenstein, M.R. et al. (September 1995) "Human IgG Anti-DNA Antibodies Deposit in Kidneys and Induce Proteinuria in SCID Mice," <i>Kidney Int.</i> 48:705-711.
114.	Ehrich, E. et al. (September 1998). "Improvements in SF-36 Mental Health Domains with Treatment of OA: A Result of Decreased Pain and Disability or Independent Mechanisms?" <i>Arthritis & Rheumatism</i> 41(9):S221:Abs. no. 1134.
115.	Ehrich, E.W. et al. (November 2000). "Minimal Perceptible Clinical Improvement with the Western Ontario and McMaster Universities Osteoarthritis Index Questionnaire and Global Assessments in Patients with Osteoarthritis," <i>J. Rheumatol.</i> 27(11):2635-2641.
116.	Ferguson, P.J. et al (February 1995). "Antigen-Based Heteropolymers: A Potential Therapy for Binding and Clearing Autoantibodies Via Erythrocyte CR1," <i>Arthritis & Rheumatism</i> 38(2):190-200.
117.	Ferguson, P.J. et al. (September 1994). "Antigen-Based Heteropolymers (AHP): A Potential Therapeutic to Bind and Clear Autoantibodies via Erythrocyte (E) CR1," <i>Arthritis & Rheumatism</i> 37 (9):S406:Abs. no. 1467.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 6, 2005	

118.	Finkelman, F.D. et al. (February 1995). "Cross-linking of Membrane Immunoglobulin D, in the Absence of T Cell Help, Kills Mature B Cells In Vivo," <i>J. Exp. Med.</i> 181:515-525.
119.	Fortin, P.R. et al. (1998) "Impact of Disease Activity and Cumulative Damage on the Health of Lupus Patients," <i>Lupus</i> 7:101-107.
120.	Foster, M.H. et al. (November 1993). "Biology of Disease: Nephritogenic Autoantibodies in Systematic Lupus Erythematosus: Immunochemical Properties, Mechanisms of Immune Deposition, and Genetic Origins," <i>Laboratory Investigation</i> 69(5):494-507.
121.	Furie, R.A. et al. (February 2001). "Treatment of Systemic Lupus Erythematosus with LJP 394," posted on < http://www.ljpc.com/abstracts/abstract_2001_16.html > last visited on October 21, 2004 (1 page).
122.	Furie, R.A. et al. (February 2001). "Treatment of Systemic Lupus Erythematosus with LJP 394," <i>J. Rheumatol.</i> 28(2):257-265.
123.	Gaynor, B. et al. (March 1997). "Peptide Inhibition of Glomerular Deposition of an Anti-DNA Antibody," <i>Proc. Natl. Acad. Sci. USA</i> 94:1955-1960.
124.	Gilboe, I.M. et al. (August 1999). "Health Status in Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Healthy Controls," <i>J. Rheumatol.</i> 26(8):1694-1700.
125.	Gladman, D.D. et al. (May 1996). "Lack of Correlation Among the 3 Outcomes Describing SLE: Disease Activity, Damage, and Quality of Life," <i>Clin. Exp. Rheumatol.</i> 14:305-308.
126.	Gladman, D. et al. (November 1996). "Systemic Lupus International Collaborating Clinics Conference on Assessment of Lupus Flare and Quality of Life Measures in SLE," <i>J. Rheumatol.</i> 23(11):1953-1955.
127.	Gladman, D.D. et al. (June 1996). "A Comparison of Five Health Status Instruments in Patients with Systemic Lupus Erythematosus (SLE)," <i>Lupus</i> 5:190-195.
128.	Goldsmith, C.H. et al. (March 1993). "Criteria for Clinically Important Changes in Outcomes: Development, Scoring, and Evaluation of Rheumatoid Arthritis Patient and Trial Profiles," <i>J. Rheumatol.</i> 20(3):561-565.
129.	Hahn, B.H. (May 1998). "Mechanisms of Disease: Antibodies to DNA," <i>N. Engl. J. Med.</i> 338(19):1359-1368.
130.	Hanly, J.G. (1997). "Disease Activity, Cumulative Damage and Quality of Life in Systematic Lupus Erythematosus: Results of a Cross-Sectional Study," <i>Lupus</i> 6:243-247.
131.	Hartley, S.B. et al. (February 1993). "Elimination of Self-Reactive B Lymphocytes Proceeds in Two Stages: Arrested Development and Cell Death," <i>Cell</i> 72:325-335.
132.	Henderson, A.L. et al. (December 2002). "Concerted Clearance of Immune Complexes Bound to the Human Erythrocyte Complement Receptor: Development of a Heterologous Mouse Model," <i>J. Immunol. Methods</i> 270(2):183-197.
133.	Hepburn, B. et al. (September 1996). "Reduction of Anti-ds DNA Antibodies Using LJP-394 in Patients with Lupus," <i>Arthritis & Rheumatism</i> 39(9):S307:Abs no. 1675.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 12, 2005	

134.	Hepburn, B. et al. (October 1996). "Reduction of Anti-ds DNA Antibodies Using LJP 394 in Patients with Lupus," abstract presented at <i>The American College of Rheumatology's 60th National Meeting</i> , Oct. 21, 1996, Orlando FL, as posted on < http://www.ljpc.com/abstracts/abstract_1996_reduction.html > last visited on April 9, 2004 (2 pages).
135.	Hochberg, M.C. et al. (September 1985). "Systemic Lupus Erythematosus: A Review of Clinico-Laboratory Features and Immunogenetic Markers in 150 Patients with Emphasis on Demographic Subsets," <i>Medicine</i> 64(5):285-295.
136.	Iking-Konert, C. et al. (September 2002). "Evaluation of Safety and Efficiency of Lowering Antibodies to dsDNA Following a Single Intravenous Administration of the Novel Monoclonal Antibody ET1104 in Patients with Systemic Lupus Erythematoses," <i>Arthritis & Rheumatism</i> 46(9):S292-S292: Abs. no. 728.
137.	International Search Report mailed on November 4, 2004, for PCT Patent Application No. PCT/US2004/010099 filed on March 30, 2004, 3 pages.
138.	Jones, D.S. et al. (September 1994). "Conjugates of Double-Stranded Oligonucleotides with Poly(ethylene glycol) and Keyhole Limpet Hemocyanin: A Model for Treating Systemic Lupus Erythematosus," <i>Bioconjugate Chem.</i> 5(5):390-399.
139.	Jones, D.S. et al. (March 1994). "LJP-294: A New Oligonucleotide Conjugate for Suppression of Anti-Double Stranded DNA Antibodies," <i>Abstracts of Papers American Chemical Society</i> 207:BIOT, Abs. no.113.
140.	Jones, D.S. et al. (June 1995). "Immunospecific Reduction of Antiloligonucleotide Antibody-Forming Cells with a Tetrakis-oligonucleotide Conjugate (LJP 394), a Therapeutic Candidate for the Treatment of Lupus Nephritis," <i>J. Med. Chem.</i> 38(12):2138-2144.
141.	Jones, D.S. et al. (November 2003). "Multivalent Poly(Ethylene Glycol) -Containing Conjugates for In Vivo Antibody Suppression," <i>Bioconjugate Chemistry</i> 14(6):1067-1076.
142.	Jones, D.S. (June 1991). "Case Study: Lupus Nephritis," <i>American Nephrology Nurses' Association</i> 18(3):327-329.
143.	Kavanaugh, A. et al. (September 2000). "Infliximab Improves Long-term Quality of Life and Functional Status in Patients with Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> 43(9):S147. Abs. no. 483.
144.	Klippel, J.H. et al. (April 1990). "Systemic Lupus Erythematosus: Treatment-Related Complications Superimposed on Chronic Disease," <i>JAMA</i> 263(13):1812-1815.
145.	Kosinski, M. et al. (September 2000). "Determining Clinically Meaningful Improvement in SF-36 Scale Scores for Treatment Studies in Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> 43(9S):S140: Abs. no. 439.
146.	Kosinski, M. et al. (July 2000) "Determining Minimally Important Changes in Generic and Disease-Specific Health-Related Quality of Life Questionnaires in Clinical Trials of Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> 43(7):1478-1487.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 6, 2005	

147.	Kozora, E. et al. (December 1996). "Analysis of Cognitive and Psychological Deficits in Systemic Lupus Erythematosus Patients Without Overt Central Nervous System Disease," <i>Arthritis & Rheumatism</i> . 39(12):2035-2045.
148.	La Jolla Pharmaceutical Co. (February 16, 2000). "Lupus Trial Results Show Significant Improvement in Time to Renal Flare in Subpopulation," located at < http://www.ljpc.com/pressrelease/0216_00.html > last visited on June 27, 2004 (2 pages).
149.	La Jolla Pharmaceutical Co. (February 18, 2003). "La Jolla Pharmaceutical Announces Results of Phase III Trial of Riquent," located at < http://www.ljpc.com/pressrelease/0218_03.html > last visited on April 9, 2004 (7 pages).
150.	La Jolla Pharmaceutical Co. (February 25, 2002). "La Jolla Pharmaceutical Scientists Present at Two International Autoimmune Disease Medical Conferences," located at < http://www.ljpc.com/pressrelease/0225_02.html > last visited on April 9, 2004 (3 pages).
151.	La Jolla Pharmaceutical Co. (January 10, 2002). "Impact of La Jolla Pharmaceutical's Lupus Drug Candidate on Patients' Health-Related Quality of Life Presented at NIH Conference," located at < http://www.ljpc.com/pressrelease/0110_02.html > last visited on April 9, 2004 (3 pages).
152.	La Jolla Pharmaceutical Co. (June 11, 2001). "La Jolla Pharmaceutical's Phase III Trial Expands to Europe," located at < http://www.ljpc.com/pressrelease/0611_01.html > last visited on June 27, 2004 (2 pages).
153.	La Jolla Pharmaceutical Co. (June 16, 2003). "La Jolla Pharmaceutical Announces Health-Related Quality of Life Results from Riquent Phase 3 Trial," located at < http://www.ljpc.com/pressrelease/0616_03.html > last visited on April 9, 2004 (5 pages).
154.	La Jolla Pharmaceutical Co. (March 31, 2003). "Results from Two Riquent Trials Show Lupus Patients with Sustained Reductions in Antibodies to dsDNA Have Fewer Renal Flares," located at < http://www.ljpc.com/pressrelease/0331_03.html > last visited on April 9, 2004 (4 pages).
155.	La Jolla Pharmaceutical Co. (May 4, 2000). "Lupus Clinical Trial Results Strengthened," located at < http://www.ljpc.com/pressrelease/0504_00.html > last visited on June 27, 2004 (3 pages).
156.	La Jolla Pharmaceutical Co. (November 14, 2001). "Data on La Jolla Pharmaceutical's Lupus Drug Presented at ACR Shows Similar Reductions in Disease-Causing Antibodies when Compared to Immunosuppressive Drugs," located at < http://www.ljpc.com/pressrelease/1114_01.html > last visited on June 27, 2004 (3 pages).
157.	La Jolla Pharmaceutical Co. (November 17, 2003). "La Jolla Pharmaceutical Company Presents Results Linking Antibodies to dsDNA with Renal Flares," located at < http://www.ljpc.com/pressrelease/1117_03.html > last visited on April 9, 2004 (3 pages).

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January <u>6</u> , 2005	

158.	La Jolla Pharmaceutical Co. (October 18, 2000). "La Jolla Pharmaceutical to Present Lupus Results at American College of Rheumatology Meeting," located at < http://www.ljpc.com/pressrelease/1018_00.html > last visited on June 27, 2004 (2 pages).
159.	La Jolla Pharmaceutical Co. (October 31, 2000). "LJP394 Reduces Renal Flares in Lupus Patients with Poor Renal Function," located at < http://www.ljpc.com/pressrelease/1031_00.html > last visited on June 27, 2004 (3 pages).
160.	La Jolla Pharmaceutical Co. (September 19, 2000). "La Jolla Pharmaceutical Initiates Phase III Lupus Clinical Trial," located at < http://www.ljpc.com/pressrelease/0919_00.html > last visited on June 27, 2004 (3 pages).
161.	La Jolla Pharmaceutical Co. (January 11, 2001). "La Jolla Pharmaceutical Announces that in Three Clinical Trials 90% of Lupus Patients Have Key Antibodies," located at < http://www.ljpc.com/pressrelease/0111_01.html > last visited on November 22, 2004 (3 pages).
162.	La Jolla Pharmaceutical Co. (October 22, 2002). "La Jolla Pharmaceutical to Complete Enrollment of Phase III Lupus Clinical Trial," located at < http://www.ljpc.com/pressrelease/1022_02.html > last visited on November 22, 2004 (3 pages).
163.	Lee, M.L. et al. (September 1994). "Phase 1 Clinical Results with an Idiopathic Vaccine (3E10) for Systemic Lupus Erythematosus (SLE)," <i>Arthritis & Rheumatism</i> 37(9 Suppl.):368:Abs no. 1243.
164.	Lee, M.L. et al. (September 1995). "Updated Phase 1 Clinical Results with an Idiopathic Vaccine (3E10) for Systemic Lupus Erythematosus (SLE)," <i>Arthritis & Rheumatism</i> 38(9):S303. Abs. no. 901.
165.	Lefkowitz, J.B. et al. (September 1996). "Heterogeneity and Clinical Significance of Glomerular-Binding Antibodies in Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 98:1373-1380.
166.	Lindorfer, M.A. et al. (February 2001). "A Bispecific dsDNAx Monoclonal Antibody Construct for Clearance of Anti-dsDNA IgG in Systemic Lupus Erythematosus," <i>J. Immunol. Methods.</i> 248:125-138.
167.	Lindorfer, M.A. et al. (October 2001). "Heteropolymer-Mediated Clearance of Immune Complexes Via Erythrocyte CR1: Mechanisms and Applications," <i>Immunol. Rev.</i> 183:10-24.
168.	Lindorfer, M.A. et al. (March 2002). "IgG Anti-dsDNA Autoantibodies Bound to the Primate Erythrocyte Complement Receptor (CR1) Via a Bispecific Construct are Cleared to the Murine Liver in a Concerted Reaction," <i>FASEB J.</i> 16(4):A681:Abs no. 510.2.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 12, 2005	

169.	Linnik, M.D. et al (February 2002). "Effect of LJP 394, High Dose Corticosteroids and Cyclophosphamide (HDCC) on Anti-dsDNA Antibodies in SLE Patients," abstract <i>presented at the 3rd International Congress on Autoimmunity</i> , February 20-24, 2002, Geneva, Switzerland, as posted on < http://www.ljpc.com/abstracts/abstract_2002_02.html > last visited on April 9, 2004 (2 pages).
170.	Linnik, M.D. et al (February 2002). "Reduction in Antibodies to dsDNA Using LJP 394 in Dose Ranging Trial in Lupus Patients," abstract <i>presented at the 3rd International Congress on Autoimmunity</i> , February 20-24, 2002, Geneva, Switzerland, as posted on < http://www.ljpc.com/abstracts/abstract_2002_01.html > last visited on April 9, 2004 (2 pages).
171.	Linnik, M.D. et al (February 2002). "Effect of LJP 394 or High Dose Corticosteroids and Cyclophosphamide on Anti-dsDNA Antibodies in SLE Patients," abstract <i>presented at the Keystone Symposium: "Mechanisms & Applications of Immune Tolerance"</i> , April 3-9, 2002, Steamboat Springs, CO, as posted on < http://www.ljpc.com/abstracts/abstract_2002_05.html > last visited on April 9, 2004 (2 pages).
172.	Linnik, M.D. et al (November 2003). "Reductions in Anti-dsDNA Antibodies and Reduced Risk of SLE Renal Flare and Major SLE Flare," abstract <i>presented at the 36th Annual Meeting of the American Society of Nephrology</i> , November 12-17, 2003, San Diego, CA, as posted on < http://www.ljpc.com/abstracts/abstract_2003_09.html > last visited on June 27, 2004 (2 pages).
173.	Linnik, M.D. et al. (September 2000). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLE Patients with Positive dsDNA Antibody Titers," <i>Arthritis & Rheumatism</i> 43(9):S241:Abs. no. 1045.
174.	Linnik, M.D. et al. (September 2000). "Effect of LJP 394 on Patients with Greatest Impairment of Renal Function at Baseline in the 90-05 Trial," <i>Arthritis & Rheumatism</i> 43(9):S241:Abs. no. 1046.
175.	Linnik, M.D. et al. (October 2000). "Effect of LJP 394 on Patients with Greatest Impairment of Renal Function at Baseline in the 90-05 Trial," abstract <i>presented at the 64th Annual Scientific Meeting of the American College of Rheumatology</i> , Oct. 29-Nov. 2, 2000, Philadelphia, PA, as posted on < http://www.ljpc.com/abstracts/abstract_2000_effect.html > last visited on December 8, 2003 (1 page).
176.	Linnik, M.D. et al. (March 2000). "Reduction in Anti-dsDNA Antibodies by LJP 394 in Lupus Patients is Influenced by Affinity for the LJP 394 dsDNA Epitope," abstract <i>presented at the Keystone Symposia 2000 "Mechanisms of Immunologic Tolerance and its Breakdown"</i> , Mar. 31-April 6, 2000, Steamboat Springs, CO, as posted on < http://www.ljpc.com/abstracts/abstract_2000_reduction.html > last visited on April 9, 2004 (2 pages).

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 18, 2005	

177.	Linnik, M.D. et al. (September 2001). "Effect of LJP 394 or High Dose Corticosteroids and Cyclophosphamide on Anti-dsDNA Antibodies in SLE Patients," <i>Arthritis & Rheumatism</i> 44(9):S282: Abs. no. 1378.
178.	Linnik, M.D. et al. (March 2001). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLE Patients," <i>Lupus</i> 10(Supp 1):S52: Abs no. 30.
179.	Linnik, M.D. et al. (March 2001). "Affinity of Antibodies for LJP 394 Influences Pharmacodynamic Response to LJP 394 in SLE Patients," abstract <i>presented at The 6th International Lupus Conference</i> , Mar. 24-28, 2001, Barcelona, Spain, as posted on < http://www.ljpc.com/abstracts/abstract_2001_04.html > last visited on December 8, 2003. (1 page).
180.	Linnik, M.D. et al. (March 2001). "Effect of LJP 394 on SLE Patients with Impaired Renal Function," abstract <i>presented at The 6th International Lupus Conference</i> , Mar. 24-28, 2001, Barcelona, Spain, as posted on < http://www.ljpc.com/abstracts/abstract_2001_03.html > last visited on April 9, 2004 (2 pages).
181.	Linnik, M.D. et al. (November 2001). "Effect of LJP 394 or High Dose Corticosteroids and Cyclophosphamide on Anti-dsDNA Antibodies in SLE Patients," abstract <i>presented at the 65th Annual Scientific Meeting of the American College of Rheumatology</i> , Nov. 11-15, 2001, San Francisco, CA, as posted on < http://www.ljpc.com/abstracts/abstract_2001_09.html > last visited on April 9, 2004 (2 pages).
182.	Linnik, M.D. et al. (March 2001). "Effect of LJP 394 on SLE Patients with Impaired Renal Function," <i>Lupus</i> 10(Supp 1):S17: Abs no. 19.
183.	Linnik, M.D. et al. (December 2002). "Workshop Report on Some New Ideas about the Treatment of Systemic Lupus Erythematosus," <i>Lupus</i> 11(12):793-796.
184.	Linnik, M.D. et al. (2002). "Workshop Report on Some New Ideas about the Treatment of Systemic Lupus Erythematosus," as posted on < http://www.ljpc.com/abstracts/abstract_2002_10.html > last visited on November 12, 2004. (1 page).
185.	Linnik, M.D. et al. (November 2003). "Reductions in Anti-dsDNA Antibodies and Reduced Risk of SLE Renal Flare and Major SLE Flare," <i>Journal of the American Society of Nephrology</i> 14:450A: Abs. no. SA-PO695.
186.	Linnik, M.D. et al. (September 2003). "SLE Patients with Sustained Reductions in Anti-dsDNA Antibodies have a Reduced Risk of Renal Flare and Major SLE Flare," <i>Arthritis & Rheumatism</i> 48(9):S582. Abs no. 1501.
187.	Linnik, M.D. et al. (October 2003). "SLE Patients with Sustained Reductions in Anti-dsDNA Antibodies Have a Reduced Risk of Renal Flare and Major SLE Flare," abstract <i>presented at the 67th Annual Meeting of the American College of Rheumatology</i> , October 23-28, 2003, Orlando, FL, as posted on < http://www.ljpc.com/abstracts/abstract_2003_05.html > last visited on June 27, 2004 (2 pages).

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 4, 2005	

188.	McNeeley, P.A. et al. (August 2001). "Pre-Treatment Affinity for LJP 394 Influences Pharmacodynamic Response in Lupus Patients," <i>Lupus</i> 10(8):526-532.
189.	McNeeley, P.A. et al. (March 2001). "Pre-Treatment Affinity for LJP 394 Influences Pharmacodynamic Response in Lupus Patients," as posted on < http://www.ljpc.com/abstracts/abstract_2001_13.html > last visited on December 8, 2003. (1 page).
190.	McNeeley, P.A. et al. (October 2000). "Lupus Patient Pharmacodynamic Response to LJP 394 is Influenced by Pre-Treatment Antibody Affinity for LJP 394," abstract <i>presented at The 26th Annual Conference of the La Jolla Immunologists</i> , Oct. 24-25, 2000, La Jolla, CA, as posted on < http://www.ljpc.com/abstracts/abstract_2000_pharmaco_response.html > last visited on April 9, 2004 (2 pages).
191.	Morimoto, C. et al. (November 1982). "Correlation Between Clinical Activity of Systemic Lupus Erythematosus and the Amounts of DNA in DNA/Anti-DNA Antibody Immune Complexes," <i>J. Immunol.</i> 139(5):1960-1965.
192.	Norvell, A. et al. (May 1995). "Engagement of the Antigen-Receptor on Immature Murine B Lymphocytes Results in Death by Apoptosis," <i>J. Immunol.</i> 154(9):4404-4413.
193.	Ortmann, R.A. et al. (May 2000). "Update on Cyclophosphamide for Systemic Lupus Erythematosus," <i>Rheum. Dis. Clin. North Am.</i> 26(2):363-375.
194.	Petri, M. et al. (September 1997). "Results of the GL701 (DHEA) Multicenter Steroid-Sparing SLE Study," <i>Arthritis & Rheumatism</i> 40(9):S327:Abs no. 1769.
195.	Petri, M.A. et al. (July 2002). "Effects of Prasterone on Corticosteroid Requirements of Women with Systemic Lupus Erythematosus-A Double-Blind, Randomized, Placebo-Controlled Trial," <i>Arthritis & Rheumatism</i> 46(7):1820-1829.
196.	Pincus, S.E. et al. (November 2002). "Evaluation of Antigen-Based Heteropolymer for Treatment of Systemic Lupus Erythematosus in a Nonhuman Primate Model," <i>Clinical Immunol.</i> 105(2):141-154.
197.	Pistiner, M. et al. (August 1991). "Lupus Erythematosus in the 1980s: A Survey of 570 Patients," <i>Semin. Arthritis Rheum.</i> 21(1):55-64.
198.	Plunkett, M.L et al. (1995). "LJP 394: A Novel Clinical Candidate for the Treatment of Lupus Nephritis," <i>Lupus</i> 4:S99.
199.	Putterman, C. et al. (July 1998). "Immunization with a Peptide Surrogate for Double-Stranded DNA (dsDNA) Induces Autoantibody Production and Renal Immunoglobulin Deposition," <i>J. Exp. Med.</i> 188(1):29-38.
200.	Rood, M.J. et al. (August 2000). "Sensitivity to Change of the MOS SF-36 Quality of Life Assessment Questionnaire in Patients with Systemic Lupus Erythematosus Taking Immunosuppressive Therapy," <i>J. Rheumatol.</i> 27(8):2057-2059.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 6, 2005	

201.	Rothfield, N.F. et al. (July 1967). "The Relation of Immunoglobulin Class, Pattern of Anti-nuclear Antibody and Complement-Fixing Antibodies to DNA in Sera from Patients with Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 46(11):1785-1794
202.	Saffran, D.C. et al. (April 2002). "Treatment of Antibody-Mediated SLE-Like Disease in Male BXS ^B Mice with a B-Cell Toleragen Specific for Anti-dsDNA Antibodies," abstract presented at the <i>Keystone Symposium: Mechanisms & Applications of Immune Tolerance</i> , April 3-9, 2002, Steamboat Springs, CO, as posted on < http://www.ljpc.com/abstracts/abstract_2002_04.html > last visited on December 8, 2003 (1 page).
203.	Samsa, G. et al. (February 1999). "Determining Clinically Important Differences in Health Status Measures: A General Approach with Illustration to the Health Utilities Index Mark II," <i>Pharmacoeconomics</i> 15(2):141-155.
204.	Seleznick, M.J. et al. (October 1991). "Variables Associated with Decreased Survival in Systemic Lupus Erythematosus," <i>Semin. Arthritis Rheum.</i> 21(2):73-80.
205.	Sem, D.S. et al. (December 1999). "Antibody Affinities and Relative Titers in Polyclonal Populations: Surface Plasmon Resonance Analysis of Anti-DNA Antibodies," <i>Arch. Biochem. Biophys.</i> 372(1):62-68.
206.	Simon, G.E. et al. (1998). "SF-36 Summary Scores: Are Physical and Mental Health Truly Distinct?" <i>Med Care</i> 36(4):567-572.
207.	Smeenk, R.J.T. et al. (1991). "Serology: Anti-dsDNA: Choice of Assay in Relation to Clinical Value," <i>Rheumatol. Int.</i> 11:101-107
208.	Smolen, J.S. et al. (1999) "Randomized Clinical Trials and Longitudinal Observational Studies in Systemic Lupus Erythematosus: Consensus on a Preliminary Core Set of Outcome Domains," <i>J. Rheumatol.</i> 26(2):504-507.
209.	Stafford, F.J. et al. (1994). "A Pilot Study of Anti-CD5 Ricin A Chain Immunoconjugate in Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 21(11):2068-2070.
210.	Stoll, T. et al. (July 1997). "Consistency and Validity of Patient Administered Assessment of Quality of Life by the MOS SF-36; Its Association with Disease Activity and Damage in Patients with Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 24(8): 1608-1614.
211.	Strand, V. et al. (1997). "Approaches to the Management of Systemic Lupus Erythematosus," <i>Current Opinion in Rheumatology</i> 9:410-420.
212.	Strand, V. et al. (1999). "Outcome Measures to be Used in Clinical Trials in Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 26(2):490-497.
213.	Strand, V. et al. (January 2000). "Endpoints: Consensus Recommendations from OMERACT IV," <i>Lupus</i> 9:322-327.
214.	Strand, V. et al. (May 2000). "New Therapies for Systemic Lupus Erythematosus," <i>Rheumatic Disease Clinics of North America</i> 26(2):389-406.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 6, 2005	

215.	Strand, V. et al. (September 2001). "Correlation of Health Assessment Questionnaire (HAQ) With Short Form-36 (SF-36): Comparison of Leflunomide (LEF) With Methotrexate (MTX) in Patients with Active Rheumatoid Arthritis (RA)," <i>Arthritis & Rheumatism</i> 44(9):S187: Abs. no. 808.
216.	Strand, V. et al. (March 2001). "Monoclonal Antibodies and Other Biologic Therapies," <i>Lupus</i> 10:216-221.
217.	Strand, V. et al. (September 2001). "Use of Minimum Clinically Important Differences (MCID) in Evaluating Patient Responses to Treatment of Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> 44(9):S187: Abs. no. 810.
218.	Strand, V. et al. (January 2002). "Improvement in Health-Related Quality of Life [HRQOL] in 230 SLE Patients Enrolled in a Randomized Controlled Trial [RCT] Comparing LJP 394 Treatment with Placebo," abstract <i>presented at the SLE: Targets for New Therapeutics: A Scientific Conference</i> , Jan. 10-12, 2002, Bethesda, MD (1 page).
219.	Strand, V. et al. (October 2002). "Improvement in Health-Related Quality of Life in SLE Patients Enrolled in a Randomized Clinical Trial Comparing LJP 394 with Placebo," abstract <i>presented at the American College of Rheumatology</i> , October 26, 2002, New Orleans, LA, as posted on < http://www.ljpc.com/abstracts/abstract_2002_08.html > last visited on April 9, 2004 (2 pages).
220.	Strand, V. et al. (September 2002). "Improvement in Health-Related Quality of Life in SLE Patients Enrolled in a Randomized Clinical Trial Comparing LJP 394 Treatment with Placebo," <i>Arthritis & Rheumatism</i> 46(9):S119: Abs. no. 221.
221.	Strand, V. et al. (June 2001). "New Therapies in Development for Autoimmune Diseases: Their Rationale for Combination Treatment," <i>Springer Seminars in Immunopathology</i> 23:46-61.
222.	Strand, V. et al. (August 2003). "Improvement in Health-Related Quality of Life in Systemic Lupus Erythematosus Patients Enrolled in a Randomized Clinical Trial Comparing LJP 394 Treatment with Placebo," <i>Lupus</i> 12:677-686.
223.	Strand, V. (September 1999). "Biologic Agents and Innovative Interventional Approaches in the Management of Systemic Lupus Erythematosus," <i>Current Opinion of Rheumatology</i> 11(5):330-340.
224.	Swaak, A.J.G. et al. (1986). "Predictive Value of Complement Profiles and Anti-dsDNA in Systemic Lupus Erythematosus," <i>Ann. Rheum. Dis.</i> 45:359-366.
225.	Tan, E.M. et al. (November 1982). "The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus," <i>Arthritis & Rheumatism</i> 25:1271-1277.
226.	Taylor, R.P. et al. (1995). "Immune Complexes (IC) Bound to Erythrocyte (E) CR1 via Anti-CR1 Mabs are Cleared Simultaneously with Loss of E CR1 in a Concerted Reaction in a Rhesus Monkey Model," <i>Arthritis & Rheumatism</i> 38(6):S320: Abs. no. 1000.
227.	Taylor, R.P. et al. (1995). "Primate Erythrocyte (E) Complement Receptor (CR1) as an

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 252312008000	Application Number 10/814,555
		Applicant Matthew D. LINNIK et al.	
		Filing Date March 30, 2004	Group Art Unit 1645
		Mailing Date January 4, 2005	
		Anchor Site for Bispecific-Based Therapies to Clear Pathogens or Autoantibodies Safely from the Circulation,” <i>J. of Hematotherapy</i> 4:357-362.	
	228.	ter Borg, E.J. et al. (May 1990). “Measurement of Increases in Anti-double-stranded DNA Antibody Levels as a Predictor of Disease Exacerbation in Systemic Lupus Erythematosus,” <i>Arthritis Rheum.</i> 33(5):634-643.	
	229.	Thumboo, J. et al. (1999). “Validation of the MOS SF-36 for Quality of Life Assessment of Patients with Systemic Lupus Erythematosus in Singapore,” <i>J Rheumatol</i> 26(1):97-102	
	230.	Thumboo, J. et al. (2000). “A Prospective Study of Factors Affecting Quality of Life in Systemic Lupus Erythematosus,” <i>J. Rheumatol.</i> 27(6):1414-1420.	
	231.	Tugwell, P. et al. (March 2000). “Clinical Improvement as Reflected in Measures of Function and Health-Related Quality of Life Following Treatment with Leflunomide Compared With Methotrexate in Patients with Rheumatoid Arthritis,” <i>Arthritis & Rheumatism</i> 43(3):506-514.	
	232.	Tumlin, J.A. et al (November 2003). “Efficacy Results from a RCT of LJP 394 in SLE Patients with History of Renal Disease,” abstract <i>presented at the 36th Annual Meeting of the American Society of Nephrology</i> ”, November 12-17, 2003, San Diego, CA, as posted on < http://www.ljpc.com/abstracts/abstract_2003_10.html > last visited on June 27, 2004 (2 pages).	
	233.	Tumlin, J.A. et al. (September 2001). “The B-Cell Toleragen LJP-394 Reduces Renal Flares In Patients with Lupus Nephritis: A Prospective, Double-Blinded, Placebo-Controlled Trial,” <i>Journal of American Society of Nephrology</i> 12:253A Abs. no. A1300.	
	234.	Tumlin, J.A. et al. (October 2001). “The B-Cell Toleragen LJP-394 Reduces Renal Flares In Patients with Lupus Nephritis: A Prospective, Double-Blinded, Placebo-Controlled Trial,” abstract <i>presented at ASN/ISN World Congress of Nephrology 2001</i> , October 10-17, 2001, San Francisco, CA, as posted on < http://www.ljpc.com/abstracts/abstract_2001_08.html > last visited on December 8, 2003 (2 pages).	
	235.	Tumlin, J.A. et al. (November 2003). “Renal Flare in SLE Patients with Impaired Renal Function in a RCT of LJP 394,” abstract <i>presented at the 36th Annual Meeting of the American Society of Nephrology</i> ”, November 12-17, 2003, San Diego, CA, as posted on < http://www.ljpc.com/abstracts/abstract_2003_12.html > last visited on June 27, 2004 (2 pages).	
	236.	Vitali, C. et al. (September 1992). “Disease Activity in Systemic Lupus Erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research: A Descriptive Analysis of 704 European Lupus Patients,” <i>Clin. Exp. Rheumatol.</i> 10:527-539.	
	237.	Vlahakos, D.V. et al. (June 1992). “Anti-DNA Antibodies Form Immune Deposits at Distinct Glomerular and Vascular Sites,” <i>Kidney Int.</i> 41:1690-1700.	
	238.	Vu, T.V. et al. (December 1999). “A Comparison of the Quality of Life of Patients with	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312008000	Application Number 10/814,555
	Applicant Matthew D. LINNIK et al.	
	Filing Date March 30, 2004	Group Art Unit 1645
	Mailing Date January 14 2005	

		Systemic Lupus Erythematosus With and Without Endstage Renal Disease," <i>J. Rheumatol.</i> 26(12):2595-2601.
	239.	Wacholtz, M.C. et al. (September 1991). "Treatment of Lupus Nephritis with CD5 Plus, An Immunoconjugate of Anti-CD5 Monoclonal Antibody and Ricin A Chain," <i>Arthritis & Rheumatism</i> 34(9):S58:Abs. no. 154.
	240.	Wallace, D.J. et al. (September 2003). "Safety Results from a Randomized Controlled Trial (RCT) of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease," <i>Arthritis & Rheumatism</i> 48(9):S583. Abs no. 1504.
	241.	Wallace, D.J. et al. (October 2003). "Safety Results from a Randomized Controlled Trial (RCT) of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease," abstract <i>presented at the 67th Annual Meeting of the American College of Rheumatology</i> , Oct. 23-28, 2003, Orlando, FL, as posted on < http://www.ljpc.com/abstracts/abstract_2003_06.html > last visited on December 8, 2003 (2 pages).
	242.	Wallace, D.J. et al. (November 2003). "Safety Results from a RCT of LJP 394 in SLE Patients with a History of Renal Disease," <i>Journal of the American Society of Nephrology</i> 14:449A. Abs. no. SA-PO692.
	243.	Wallace, D.J. et al. (November 2003). "Safety Results from a RCT of LJP 394 in SLE Patients with a History of Renal Disease," abstract <i>presented at the 36th Annual Meeting of the American Society of Nephrology</i> , Nov. 12-17, 2003, San Diego, CA, as posted on < http://www.ljpc.com/abstracts/abstract_2003_11.html > last visited on December 8, 2003 (2 pages).
	244.	Wallace, D.J. (January 2001). "Clinical and Pharmacological Experience with LJP-394," <i>Expert Opinion of Investigational Drugs</i> 10(1):111-117.
	245.	Wang, C. et al. (March 2001). "The Relationship Between Health Related Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 28(3):525-532.
	246.	Ware, J.E. et al. (June 1992). "The MOS 36-Item Short-Form Health Survey (SF-36)," <i>Medical Care</i> 30(6):473-483.
	247.	Ware, J.E. et al. (1993). <i>SF-36 Health Survey Manual and Interpretation Guide</i> . The Health Institute, Nimrod Press: Boston, MA., pp.3:4-3:10.
	248.	Weisman, M.H. (February 1997). "Reduction in Circulating dsDNA Antibody Titer After Administration of LJP 394," <i>J. Rheumatol.</i> 24(2):314-338.
	249.	Wells, G.A. (March 1993). "Minimum Important Difference Between Patients with Rheumatoid Arthritis: The Patient's Perspective," <i>J. of Rheumatol.</i> 20(3):557-560.
	250.	Winfield, J.B. et al. (January 1977). "Avidity of Anti-DNA Antibodies in Serum and IgG Glomerular Eluates from Patients with Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 59:90-96.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312008000

Application Number 10/814,555

Applicant

Matthew D. LINNIK et al.

Filing Date March 30, 2004

Group Art Unit 1645

Mailing Date January 12, 2005

- | | |
|------|---|
| 251. | Wyrwich, K.W. et al. (May 1999). "Linking Clinical Relevance and Statistical Significance in Evaluating Intra-Individual Changes in Health-Related Quality of Life," <i>Medical Care</i> 37(5):469-478. |
| 252. | Wyrwich, K.W. et al. (September 1999). "Further Evidence Supporting an SEM- Based Criterion for Identifying Meaningful Intra-Individual Changes in Health-Related Quality of Life," <i>J. Clin. Epidemiol.</i> 52(9):861-873. |
| 253. | Zhao, S.Z. et al. (November 1999). "Evaluation of the Functional Status Aspects of Health-Related Quality of Life of Patients with Osteoarthritis Treated with Celecoxib," <i>Pharmacotherapy</i> 19(11):1269-1278. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.